RobertLloydRuxerJr.MDFACP

Oncology • Fort Worth, TX

Hematologic Oncology, Hospice & Palliative

Physician

Join to view full profile

Dr. Ruxer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ruxer's full profile

Already have an account?

Office
500 S Henderson St
Ste 200
Fort Worth, TX 76104
Phone+1 817-413-1500

Fax+1 817-413-1499
Is this information wrong?

Education & Training

University of MarylandFellowship, Hematology and Medical Oncology, 1981 - 1983
Wright-Patterson Medical CenterResidency, Internal Medicine, 1978 - 1981
Virginia Commonwealth University School of MedicineClass of 1978

Certifications & Licensure

TX State Medical License 1994 - 2025
MD State Medical License 1981 - 1995
OH State Medical License 1979 - 1982
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Super Doctor SuperDoctors.com

Clinical Trials

Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer Start of enrollment: 2011 Jan 11
Terminated
Phase 3
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer Start of enrollment: 2011 Apr 01
Terminated
Phase 3
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 02
Terminated
Phase 3

Publications & Presentations

PubMed

32 citations
A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal ...
Daniel W. Bowles, Mark D. Kochenderfer, Allen Lee Cohn, Lucas Sideris, Nghia Nguyen
Clinical Colorectal Cancer. 2016-12-01
10 citations
Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.
Thomas H. Cartwright, Paul R. Kuefler, Allen Lee Cohn, William J. Hyman, Maury Berger
Clinical Colorectal Cancer. 2008-11-01
144 citations
Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy
Samir E. Witta, Robert M. Jotte, Katrik Konduri, Marcus A. Neubauer, Alexander I. Spira
Journal of Clinical Oncology. 2012-04-16